MBIC50 and MBEC50 values (µg/mL) of synthesized 1,2,3,5-tetrazine derivatives against bacteria pathogen strains. by Jean Paul Dzoyem (6424445)

Subjects:

Bivariate analysis of 12 Ag-RDTs. by Lukas E. Brümmer (11269299)

Drive dynamics for split^<50cM <i>ClvR</i>s with different genetic linkage and migration rates. by Georg Oberhofer (3401438)

Reproducibility of response time and brain measures. by Jan Willem Koten (17743224)

Mean liver function protein level changes over time. by Carmen Leser (3809554)

Effects of 12-week training on the tennis-specific physical fitness. by Wensheng Xiao (16557866)

Effect of sample size on reproducibility. by Jan Willem Koten (17743224)

Association of chemotherapy cycles and nausea and vomiting with the decrease of post-treatment vitamin D concentration (n = 136). by Herindita Puspitaningtyas (11618232)

Subjects:

Related to Fig 4. USP12 deficiency decreased phosphorylation of IRF3 and p65 after HSV infection. by Yuling Fu (2275756)

Primary and secondary outcomes of the randomized clinical trial groups at 3 months and 12 months. by Teemu P. Hevonkorpi (11577571)

Oral administration of TVSE decreases angiogenesis in 4T1 tumors in BALB/c mice. by Hyun Sook Lee (8039876)

The number of plasmacytoid dendritic cells (pDCs) decreased after anti-CXCR3 treatment and <i>T</i>. <i>cruzi</i> infection. by Camila Pontes Ferreira (6194006)

Histograms of mean anti-mumps antibody titers and seropositivity by vaccine dose and age (0-25 years). by Zixia Qian (21474969)

Subjects:

Demographic data of participants (mean ± SD). by Ya-Chu Chung (12551592)

Mean radiotherapy dose map of the study population. by Jesse D. de Groot (15401476)

Design of Benzyl-triazolopyrimidine-Based NADPH Oxidase Inhibitors Leads to the Discovery of a Potent Dual Covalent NOX2/MAOB Inhibitor by Beatrice Noce (16540800)

“…We found that <b>9a</b>, bearing a pargyline moiety, is also able to selectively inhibit MAOB over MAOA (465-fold) with an IC₅₀ of 0.182 μM, being the first-in-class dual NOX2/MAOB covalent inhibitor. …”

Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

“…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”

Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

“…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”

Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

“…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”

First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

“…In this study, we report the first highly selective HDAC6 inhibitor with hydrazide as the zinc-binding group (ZBG), which displays superior pharmacokinetic properties to the current hydroxamic acid inhibitors. …”